H. Brunner Et Al. , "Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial," ANNALS OF THE RHEUMATIC DISEASES , vol.82, no.1, pp.154-160, 2022
Brunner, H. Et Al. 2022. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. ANNALS OF THE RHEUMATIC DISEASES , vol.82, no.1 , 154-160.
Brunner, H., Foeldvari, I., Alexeeva, E., Ayaz, N. A., Calvo Penades, I., KASAPÇOPUR, Ö., ... Chasnyk, V. G.(2022). Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. ANNALS OF THE RHEUMATIC DISEASES , vol.82, no.1, 154-160.
Brunner, Hermine Et Al. "Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial," ANNALS OF THE RHEUMATIC DISEASES , vol.82, no.1, 154-160, 2022
Brunner, Hermine Et Al. "Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial." ANNALS OF THE RHEUMATIC DISEASES , vol.82, no.1, pp.154-160, 2022
Brunner, H. Et Al. (2022) . "Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial." ANNALS OF THE RHEUMATIC DISEASES , vol.82, no.1, pp.154-160.
@article{article, author={Hermine Brunner Et Al. }, title={Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial}, journal={ANNALS OF THE RHEUMATIC DISEASES}, year=2022, pages={154-160} }